PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold® (migalastat) in Fabry disease and POMBILITI® + OPFOLDA® (cipaglucosidase alfa plus miglustat) in late-onset Pompe disease. Data are being presented at the 22nd Annual WORLDSymposium™ 2026. “Amicus continues to advance the science and understanding of both Fabry and Pompe diseases, and we are proud to showcase new data for our me ...

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Amicus Therapeutics, Inc. tops our list for being one of the best biotech stocks. TheFly reported on January 22 that Jefferies downgraded FOLD to Buy from Hold and lowered the price target to $14.50 from $16. The company got substantial pharmaceutical takeover interest outside of BioMarin, according to proxy records, but Jefferies does not expect any more proposals. Jefferies Downgrades Amicus Therapeutics, Inc. (NASDAQ:FOLD) ...

As of Feb. 2, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to ...

Key Takeaways FOLD stands out after agreeing to a $14.50-per-share buyout by BioMarin, expected to be closed in Q2 2026.FOLD's Galafold drove over 80% of sales in 9M 2025, while Pombiliti plus Opfolda showed strong initial growth.RIGL's revenues are powered by Tavalisse, with added momentum from Rezlidhia and newly acquired Gavreto.Amicus Therapeutics (FOLD) and Rigel Pharmaceuticals (RIGL) appeal to growth-focused investors as they target rare diseases, where small patient populations can still support str ...

Core Insights - Amicus Therapeutics (FOLD) shares have surged 135.8% over the past six months, significantly outperforming the industry and the S&P 500 Index, driven by strong product momentum and a merger agreement with BioMarin Pharmaceutical (BMRN) [1][8]. Company Overview - BioMarin has agreed to acquire all outstanding shares of Amicus for $14.50 per share, totaling $4.8 billion, with the deal expected to close in Q2 2026 [3]. - Post-acquisition, BioMarin will integrate Amicus' marketed products, including Galafold (migalastat) and the combination therapy Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat), both of which have shown steady sales growth [3][4]. Product Performance - Galafold generated sales of $371.5 million in the first nine months of 2025, accounting for over 80% of Amicus' net product sales, with a year-over-year growth of approximately 12% [6][9]. - Pombiliti + Opfolda achieved sales of $77.5 million in the same period, reflecting a 61% increase year-over-year, indicating strong market potential [10]. Competitive Landscape - Amicus faces significant competition in the lysosomal storage disorder market, particularly from established players like Sanofi and Takeda, which market therapies for Fabry disease and Pompe disease [11][12][13]. - The company's heavy reliance on Galafold for revenue poses a risk, especially with increasing competition [11]. Valuation and Estimates - Amicus shares are currently trading at a price-to-sales (P/S) ratio of 7.42, which is above the industry average of 2.51, but below its five-year mean of 8.82 [14]. - The Zacks Consensus Estimate for 2025 earnings per share (EPS) has slightly increased from 34 cents to 35 cents, while estimates for 2026 have decreased from 67 cents to 65 cents [15]. Investment Outlook - The strong sales performance of Amicus' marketed products is expected to continue driving revenue growth, with incremental contributions from Pombiliti + Opfolda [17]. - Given the impending acquisition by BioMarin, investment strategies should focus on event-driven trading rather than long-term growth [18]. - Despite competitive risks, Amicus' unique positioning in the rare disease market and stable earnings estimates suggest a positive outlook, making it a potential addition for investors seeking short-term gains before the acquisition [19].

Core Insights - Corcept Therapeutics and Amicus Therapeutics reported Q3 2025 results, showcasing contrasting profitability levels within the rare disease biotech sector [1] Company Summaries Corcept Therapeutics - Corcept Therapeutics is positioned as a profitable entity within the rare disease biotech space, indicating strong financial performance [1] Amicus Therapeutics - Amicus Therapeutics, in contrast, is highlighted as being at the opposite end of the profitability spectrum, suggesting challenges in achieving financial stability [1]

Key Takeaways Galafold raked in $371.5M in the first nine months of 2025, accounting for over 80% of FOLD's product sales.Galafold benefits from broad global approvals and U.S. patent protection extending through 2038.FOLD's Pombiliti Opfolda delivered $77.5M sales in the first nine months of 2025, up 61% Y/Y.Amicus Therapeutics (FOLD) has made solid progress with its lead marketed product, Galafold (migalastat), which generates the majority of the company’s revenues.Galafold is approved for treating Fabry ...

Group 1 - BioMarin Pharmaceutical Inc. is set to acquire Amicus Therapeutics in an all-cash transaction valued at approximately $4.8 billion, with a share price of $14.50 per Amicus share [2][3] - The acquisition is expected to close in Q2 2026, pending regulatory clearances and stockholder approval [2] - This strategic move is aimed at stabilizing long-term cash flows and expanding BioMarin's leadership in rare diseases by adding two marketed therapies for lysosomal storage disorders, which generated a combined revenue of $599 million over the last four quarters [3] Group 2 - H.C. Wainwright raised BioMarin's price target to $60 from $55, maintaining a Neutral rating, indicating that Voxzogo will remain the primary driver of stock value until peak sales materialize in the 2030s [1][3] - The acquisition includes US rights to DMX-200, a Phase 3 investigational small molecule targeting focal segmental glomerulosclerosis, a rare kidney disease [3] - BioMarin develops and commercializes therapies for life-threatening rare diseases and medical conditions across various regions including the US, Europe, and Asia Pacific [4]

On December 19th, BioMarin Pharmaceutical Inc. ( BMRN ) announced it is acquiring Amicus Therapeutics, Inc. ( FOLD ) at $14.50 per share. The transaction is expected to take effect in Q2 2026. This article covers both companies, but sinceAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensa ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...